Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints
Source: SeekingAlpha
2025-10-21 17:47:06 ET
More on Terns Pharmaceuticals
- Terns Pharmaceuticals: Valued As If It Can't Win
- Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript
- Seeking Alpha’s Quant Rating on Terns Pharmaceuticals
- Historical earnings data for Terns Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints
Terns Pharmaceuticals Inc.
NASDAQ: TERN
TERN Trading
9.27% G/L:
$46.08 Last:
947,180 Volume:
$44.68 Open:
TERN Latest News
March 05, 2026 10:14:13 am
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing
February 25, 2026 04:05:00 pm
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 20, 2026 12:22:22 am
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
February 17, 2026 12:52:00 pm
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
TERN Stock Data
$3,951,236,778
84,980,644
0.19%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
Foster City
